Targeting their neomorphic enzymatic function, mutant IDH inhibitors have been designed, with Ivosidenib (IDH1) and Enasidenib (IDH2) recently approved by the Food and Drug Administration for the treatment of refractory or relapsed (R/R) AML patients with the relevant IHD mutations [49, 50]. Here, IDH2 is linked to acute myeloid leukemia.